VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously. Younger patients with group 1 paratesticular embryonal tumors and all patients with group 1/2 orbit or eyelid tumors can usually be cured with VA chemotherapy along with postoperative RT for group 2 disease.

Summary1. Gridded climatologies have become an indispensable component of bioclimatic modelling, with a range of applications spanning conservation and pest management. Such globally conformal data sets of historical and future scenario climate surfaces are required to model species potential ranges under current and future climate scenarios. 2. We developed a set of interpolated climate surfaces at 10¢ and 30¢ resolution for global land areas excluding Antarctica. Input data for the baseline climatology were gathered from the WorldClim and CRU CL1AE0 and CL2AE0 data sets. A set of future climate scenarios were generated at 10¢ resolution. For each of the historical and future scenario data sets, the full set of 35 Bioclim variables was generated. Climate variables (including relative humidity at 0900 and 1500 hours) were also generated in CLIMEX format. The Ko¨ppen-Geiger climate classification scheme was applied to the 10¢ hybrid climatology as a tool for visualizing climatic patterns and as an aid for specifying absence or background data for correlative modelling applications. 3. We tested the data set using a correlative model (MaxEnt) addressing conservation biology concerns for a rare Australian shrub, and a mechanistic niche model (CLIMEX) to map climate suitability for two invasive species. In all cases, the underlying climatology appeared to behave in a robust manner. 4. This global climate data set has the advantage over the WorldClim data set of including humidity data and an additional 16 Bioclim variables. Compared with the CRU CL2AE0 data set, the hybrid 10¢ data set includes improved precipitation estimates as well as projected climate for two global climate models running relevant greenhouse gas emission scenarios. 5. For many bioclimatic modelling purposes, there is an operational attraction to having a globally conformal historical climatology and future climate scenarios for the assessments of potential climate change impacts. Our data set is known as 'CliMond' and is available for free download from http://www.climond.org.

The results of treatment of 686, previously untreated patients younger than 21 years with rhabdomyosarcoma or undifferentiated sarcoma, who were entered on Intergroup Rhabdomyosarcoma Study-I (IRS-I) were analyzed after a minimum potential follow-up time of 7 years. Patients in Clinical Group I (localized disease, completely resected) were randomized to receive either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC + radiation. At 5 years, approximately 80% of patients given either treatment were still disease-free and there was no significant difference between treatments in the overall percentages of patients surviving of 93% and 81%, respectively (P = 0.67). Patients in Clinical Group II (regional disease, grossly resected) were randomized to receive either vincristine and dactinomycin (VA) + radiation or VAC + radiation. At 5 years, 72% and 65% of the patients, respectively, were disease-free and there was no evidence of a difference between treatments (P = 0.46). The overall survival percentage at 5 years was approximately 72% for both treatments. Patients in Clinical Groups III (gross residual disease after surgery) and IV (metastatic disease) were randomized to receive either "pulse" VAC + radiation or "pulse" VAC + Adriamycin (doxorubicin) + radiation. The complete remission (CR) rate was 69% in Clinical Group III and 50% in IV, with no statistically significant difference in CR rates between treatments in either group. Those who achieved a CR had a nearly 60% chance of staying in remission for 5 years in Clinical Group III compared with approximately 30% in Clinical Group IV. The overall survival percentage at 5 years was 52% in Clinical Group III compared to 20% in Clinical Group IV (P less than 0.0001). The 5-year survival percentage for the entire cohort of 686 patients was 55%. Survival after relapse was poor, being 32% at 1 year and 17% at 2 years. The risk of distant metastasis was much greater than the risk of local recurrence within each clinical group, and there was no evidence of differing types of relapses between treatments. Primary tumors of the orbit and genitourinary tract carried the best prognosis, whereas tumors of the retroperitoneum had the worst prognosis. The authors conclude that for the therapeutic regimens evaluated there was no therapeutic advantage to including radiation in the treatment of Clinical Group I disease, or cyclophosphamide given as a daily low-dose oral regimen in the treatment of Clinical Group II disease or Adriamycin in the treatment of Clinical Groups III and IV diseases.